Literature DB >> 1812431

Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial.

E Wedege1, G Bjune, L O Frøholm, E A Høiby, E Rosenqvist.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1812431

Source DB:  PubMed          Journal:  NIPH Ann        ISSN： 0332-5652


× No keyword cloud information.
  7 in total

1.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

3.  Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

Authors:  B Haneberg; R Dalseg; E Wedege; E A Høiby; I L Haugen; F Oftung; S R Andersen; L M Naess; A Aase; T E Michaelsen; J Holst
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

4.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

5.  Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.

Authors:  Elisabeth Wedege; Betsy Kuipers; Karin Bolstad; Harry van Dijken; L Oddvar Frøholm; Clementien Vermont; Dominique A Caugant; Germie van den Dobbelsteen
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

6.  Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway.

Authors:  E Wedege; J Kolberg; A Delvig; E A Høiby; E Holten; E Rosenqvist; D A Caugant
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

7.  Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design.

Authors:  D A Ala'Aldeen; P Stevenson; E Griffiths; A R Gorringe; L I Irons; A Robinson; S Hyde; S P Borriello
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.